FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...

Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Acquired global rights to GB3226, a novel dual ENL-YEATS and FLT3 inhibitor aimed at multiple genetic subsets of acute myeloid leukemia (AML), signaling a strategic focus on oncology. GB3226 is on ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

BMF-500, a FLT3 inhibitor, has demonstrated early signs of efficacy in the Phase I COVALENT-103 trial for relapsed/refractory acute myeloid leukemia (AML). The dose-escalation phase of the trial ...

Preclinical data showed GB3226’s superior efficacy to both FLT3 and menin inhibitors in animal models, as well as additive or synergistic activity in combination with standard-of-care treatments.

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic ...